- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01265485
An Study to Examine the Effect of Coated Suppositories on Anal Pressure in Healthy Subjects
An Open Label Study to Examine the Effect of Coated Suppositories on Anal Pressure in Healthy Subjects
This is an open label, dose-finding, 2-parts study. Approximately 6 subjects will be participating in this study. This study is composed of 2 parts:
Part 1 is a dose finding study. Part 2 is a pharmacodynamic and pharmacokinetic study of an elected dose. A screening will be used to determine patients' suitability for inclusion in the trial. Within one week after the screening visit, subjects who meet all inclusion criteria and none of the exclusion criteria will enter part 1 of the study, one day of dose escalation. During this part, patients will undergo rectal manometry to determine anal pressure at baseline. Afterwards coated suppositories at various drug concentrations will be inserted and follow up manometries will be performed to determine response.
Patients that presented with an increase in rectal resting pressure without adverse events will enter the second part of the study. In this part, patients will be administered with a coated suppository, at a dose found at part 1 of the study to cause significant anal contraction. Manometry studies will be performed before insertion (baseline) and at 1, 3 and 5 hours after insertion.
Blood levels for drug concentrations will be taken at times 0, 30, 60, 120, 180, 300 minutes after administration and rectal manometries will be done at times 0, 1, 3 and 5 hours after administration.
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Zrifin, Israel
- Gastroeneterology dept, Asaf harofe Medical center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed written informed consent.
- Male or female subjects 18 to 55 years of age;
Exclusion Criteria:
- Known allergy to the active drug or excipients.
- Pregnancy or lactation.
- Active cardiovascular or cerebrovascular disease including unstable angina, myocardial infarction, transient ischemic attacks/stroke, clinically significant arrhythmia, congestive heart failure, or cardiac valve abnormalities;
- Type 1 diabetes mellitus;
- Insulin treated type 2 diabetes mellitus;
- Renal insufficiency.
- Liver insufficiency.
- Malignant disease within 5 years of screening;
- History of rectal surgery.
- History of HIV, hepatitis B, hepatitis C.
- Has upon physical examination a rectal deformation or signs of rectal disease such as fissure, bleeding hemorrhoids, fistula, infection or space occupying lesion.
- Chronic use of medications with the exception of birth control pills.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: treatment
|
Dose escalating study
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in resting anal pressure
Time Frame: 1 day
|
The primary outcome is the change in resting anal pressure as measured 90 minutes after insertion of coated suppository and in comparison to baseline measurement taken before intervention.
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Drug absorption
Time Frame: 1 day
|
Blood samples for determining drug absorption be taken at times 0, 30, 60, 120, 180, 300 minutes after administration
|
1 day
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michael Shapiro, MD, Gastroenetrology dept, Asaf Harofe Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RDD 107
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fecal Incontinence
-
Batterjee Medical CollegeBenha UniversityCompleted
-
RDD Pharma LtdWithdrawnIdiopathic Fecal IncontinenceIsrael
-
Badr UniversityCompletedFecal Incontinence in ChildrenEgypt
-
Hospital Mutua de TerrassaCompletedGas Incontinence | Soilings, Fecal
-
Nantes University HospitalCompletedConstipation Aggravated | Fecal Incontinence With Fecal UrgencyFrance
-
Queen Mary University of LondonCompletedBowel Incontinence | Faecal Incontinence
-
University of AarhusUniversity of Tromso; Hvidovre University HospitalCompletedFecal Incontinence | Faecal IncontinenceDenmark
-
NICHD Pelvic Floor Disorders NetworkEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedFecal Incontinence | Bowel IncontinenceUnited States
-
Andalusian Initiative for Advanced Therapies -...Iniciativa Andaluza en Terapias AvanzadasCompleted
-
Massarat ZutshiCook Group IncorporatedTerminatedFecal Incontinence | Anal IncontinenceUnited States
Clinical Trials on coated suppository
-
RDD Pharma LtdWithdrawn
-
Laboratoires Techni PharmaCompleted
-
Laboratoires Techni PharmaCompleted
-
Peking University Shenzhen HospitalRecruiting
-
University of New MexicoWithdrawnInterstitial Cystitis | Bladder Pain SyndromeUnited States
-
Padagis LLCCompleted
-
Seed HealthActive, not recruitingVaginal Personal CareUnited States
-
Hatem AbuHashimUnknownVulvovaginal Candidiasis
-
Dr. Falk Pharma GmbHCompleted
-
Royal North Shore HospitalTerminatedMetastatic Castrate- Resistant Prostate CancerAustralia